Table 1.
Trial Characteristics (N = 166)
| Characteristic | No. | % |
|---|---|---|
| Sample size | ||
| Median | 836 | |
| Range | 154-4,984 | |
| Placebo controlled | 68 | 41 |
| Intervention type | ||
| Chemotherapy | 42 | 25 |
| Targeted therapy | 61 | 37 |
| Chemotherapy plus targeted therapy | 63 | 38 |
| Trial met the primary end point | 71 | 43 |
| Funding source | ||
| Industry | 111 | 67 |
| Government | 10 | 6 |
| Industry and government | 33 | 20 |
| Not reported | 12 | 7 |
| Cancer type | ||
| Breast | 38 | 23 |
| Colorectal | 17 | 10 |
| Lung | 41 | 25 |
| Gastric or Gastroesophageal | 10 | 6 |
| Other | 59 | 35 |
| Journal | ||
| Annals of Oncology | 12 | 7 |
| The New England Journal of Medicine | 10 | 6 |
| Journal of Clinical Oncology | 76 | 45 |
| Lancet Oncology | 50 | 30 |
| Other | 18 | 11 |
| Year of publication | ||
| 2011 | 49 | 30 |
| 2012 | 53 | 32 |
| 2013 | 64 | 38 |
| Impact factor of journals | ||
| Median | 19.6 | |
| Range | 3-53 | |
| Cancer stage | ||
| Adjuvant and/or neoadjuvant | 25 | 15 |
| Metastatic | 141 | 85 |